HomeBUSINESS
BUSINESS

Pfizer Files Japan NDA for Next-Gen ALK Inhibitor Lorlatinib
(Jan.31.2018)

Pfizer Japan said on January 30 that it has filed its next-generation ALK/ROS1 tyrosine kinase inhibitor (TKI), lorlatinib, for the treatment of ALK-positive, unresectable, advanced/recurrent non-small cell lung cancer (NSCLC) in patients refractory or intolerant to other ALK TKIs ...
(LOG IN FOR FULL STORY)

News Calendar